曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略  

Mechanisms of trastuzumab resistance and post-resistance treatment strategies in HER2-positive breast cancer

作　　者：王星涵(综述) 吕雅蕾(审校)[1] WANG Xinghan;LV Yalei(Department of Oncology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院肿瘤内科,石家庄050011

出　　处：《实用肿瘤学杂志》2022年第5期445-451,共7页Practical Oncology Journal

基　　金：2021年河北省政府资助临床医学优秀人才培养项目。

摘　　要：曲妥珠单抗治疗人表皮生长因子受体2(Human epidermal growth factor receptor 2,HER2)阳性乳腺癌的效果确切,但高耐药率限制了其临床应用。本文对HER2阳性乳腺癌曲妥珠单抗耐药机制进行回顾与总结,并分析耐药后HER2阳性乳腺癌的治疗策略,以期为进一步的研究及临床治疗方案制定提供参考。Trastuzumab is effective in the treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer,but the high drug resistance rate limits its clinical application.This article reviews and summarizes the mechanism of trastuzumab resistance in HER2-positive breast cancer,and analyzes the treatment strategies for HER2-positive breast cancer after drug resistance,in order to provide reference for further research and clinical treatment plan formulation.

关 键 词：曲妥珠单抗耐药 HER2阳性乳腺癌 机制 治疗 

分 类 号：R737.1[医药卫生—肿瘤]